References
- Min S , SongI, BorlandJ et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54(1) , 254–258 (2010).
- Raffi F , RachlisA, StellbrinkHJ et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority spring-2 study. Lancet 381(9868) , 735–743 (2013).
- Eron JJ , ClotetB, DurantJ et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J. Infect. Dis. 207(5) , 740–748 (2013).
- Reese MJ , SavinaPM, GenerauxGT et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos.41(2) , 353–361 (2013).
- Min S , SloanL, DejesusE et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10 day monotherapy in HIV-1-infected adults. AIDS 25(14) , 1737–1745 (2011).
- Castellino S , MossL, WagnerD et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob. Agents Chemother. 57(8) , 3536–3546 (2013).
- Bosma P , ChowdhuryJR, JansenPH. Genetic inheritance of Gilbert‘s syndrome. Lancet346(8970) , 314–315 (1995).
- Hall D , YbazetaG, Destro-BisolG, Petzl-ErlerML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics9(5) , 591–599 (1999).
- Hazama S , NagashimaA, KondoH et al. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci. 101(3) , 722–727 (2010).
- Wenning LA , PetryAS, KostJT et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin. Pharmacol. Ther. 85(6) , 623–627 (2009).
- Trontelj J , MarcJ, ZavratnikA, BogatajM, MrharA. Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol.67(4) , 437–444 (2009).
- Beutler E , GelbartT, DeminaA. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA95(14) , 8170–8174 (1998).
- Horsfall LJ , ZeitlynD, TarekegnA et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann. Hum. Genet. 75(2) , 236–246 (2011).
- Bosma PJ , ChowdhuryJR, BakkerC et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert‘s syndrome. N. Engl. J. Med. 333(18) , 1171–1175 (1995).
- Guillemette C . Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J.3(3) , 136–158 (2003).
- Song I , BorlandJ, ChenS et al. Metabolism and drug–drug interaction profile of dolutegravir. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain, 16–18 April 2012.
- van Lunzen J , MaggioloF, ArribasJR et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, Phase 2b trial. Lancet Infect. Dis. 12(2) , 111–118 (2012).
- Chen S , MinSS, PeppercornA et al. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy 32(4) , 333–339 (2012).
- Song I , BorlandJ, ChenS et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br. J. Clin. Pharmacol. 72(1) , 103–108 (2011).
- Premawardhena A , FisherCA, LiuYT et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol. Dis. 31(1) , 98–101 (2003).
▪ Website
- clinicaltrials.gov. www.clinicaltrials.gov